Poseida Therapeutics (NASDAQ:PSTX) Given “Neutral” Rating at BTIG Research

BTIG Research reaffirmed their neutral rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research note issued to investors on Tuesday morning, Marketbeat.com reports.

Several other brokerages have also recently weighed in on PSTX. William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a research report on Tuesday. HC Wainwright reaffirmed a “neutral” rating and set a $9.00 target price (down previously from $20.00) on shares of Poseida Therapeutics in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.50.

Poseida Therapeutics Price Performance

Shares of NASDAQ:PSTX opened at $9.31 on Tuesday. The firm has a market capitalization of $907.35 million, a PE ratio of -14.78 and a beta of 0.54. The company has a quick ratio of 3.20, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The company has a 50-day moving average price of $3.25 and a two-hundred day moving average price of $3.10. Poseida Therapeutics has a twelve month low of $1.87 and a twelve month high of $9.42.

Insider Buying and Selling

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total value of $278,100.00. Following the completion of the sale, the chairman now owns 651,291 shares in the company, valued at approximately $6,037,467.57. The trade was a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC purchased a new stake in Poseida Therapeutics during the 3rd quarter valued at $37,000. Barclays PLC raised its stake in shares of Poseida Therapeutics by 132.7% during the third quarter. Barclays PLC now owns 120,464 shares of the company’s stock valued at $345,000 after acquiring an additional 68,688 shares during the last quarter. XTX Topco Ltd boosted its holdings in shares of Poseida Therapeutics by 47.1% during the third quarter. XTX Topco Ltd now owns 182,888 shares of the company’s stock worth $523,000 after purchasing an additional 58,587 shares during the period. State Street Corp grew its stake in shares of Poseida Therapeutics by 2.3% in the third quarter. State Street Corp now owns 1,710,565 shares of the company’s stock worth $4,892,000 after purchasing an additional 38,770 shares during the last quarter. Finally, Fred Alger Management LLC purchased a new position in Poseida Therapeutics during the 3rd quarter valued at about $369,000. Institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.